Success Metrics

Clinical Success Rate
50.0%

Based on 4 completed trials

Completion Rate
50%(4/8)
Active Trials
8(44%)
Results Posted
75%(3 trials)
Terminated
4(22%)

Phase Distribution

Ph phase_3
3
17%
Ph early_phase_1
1
6%
Ph phase_1
3
17%
Ph phase_2
8
44%
Ph phase_4
1
6%

Phase Distribution

4

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
1(6.3%)
Phase 1Safety & dosage
3(18.8%)
Phase 2Efficacy & side effects
8(50.0%)
Phase 3Large-scale testing
3(18.8%)
Phase 4Post-market surveillance
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

8

trials recruiting

Total Trials

18

all time

Status Distribution
Active(9)
Completed(4)
Terminated(4)
Other(1)

Detailed Status

Terminated4
Completed4
Active, not recruiting4
Recruiting4
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
8
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (6.3%)
Phase 13 (18.8%)
Phase 28 (50.0%)
Phase 33 (18.8%)
Phase 41 (6.3%)

Trials by Status

terminated422%
not_yet_recruiting16%
completed422%
active_not_recruiting422%
recruiting422%
unknown16%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT05363319

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Recruiting
NCT05614102Phase 1

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Active Not Recruiting
NCT06465329Phase 2

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Recruiting
NCT07358689Phase 2

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Not Yet Recruiting
NCT04486833Phase 1

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Recruiting
NCT04966676Phase 2

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer

Terminated
NCT04906993Phase 3

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Active Not Recruiting
NCT05607550Phase 3

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Active Not Recruiting
NCT05338970Phase 3

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active Not Recruiting
NCT06775275Phase 2

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

Recruiting
NCT02489006Phase 2

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Unknown
NCT05862194

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Completed
NCT04851834Phase 1

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Terminated
NCT02855697Early Phase 1

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

Completed
NCT03322566Phase 2

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Completed
NCT00404703Phase 2

A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer

Terminated
NCT00451906Phase 4

A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Completed
NCT00391586Phase 2

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

Terminated

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18